Acceleron Pharma
XLRN
XLRN was delisted on the 19th of November, 2021.
79 hedge funds and large institutions have $593M invested in Acceleron Pharma in 2014 Q1 according to their latest regulatory filings, with 22 funds opening new positions, 29 increasing their positions, 25 reducing their positions, and 5 closing their positions.
340% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 5
27% more funds holding
Funds holding: 62 → 79 (+17)
16% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 25
13% more capital invested
Capital invested by funds: $527M → $593M (+$66.8M)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$61.3M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
+$36.9M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$36.1M |
| 4 |
Loomis, Sayles & Company
Boston,
Massachusetts
|
+$13M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$11.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
-$11.7M |
| 2 |
O
OrbiMed
New York
|
-$11.3M |
| 3 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
-$3.58M |
| 4 |
VOYA Investment Management
Atlanta,
Georgia
|
-$3.39M |
| 5 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$3.3M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
76
BlackRock
New York
| $7K | +$9.07K | +201 | New |
|
77
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
| $2.5K | +$3.27M | +72,420 | +44,429% |
|
78
BNP Paribas Financial Markets
Paris,
France
| $240 | -$3.25K | -72 | -91% |
|
79
Wellington Management Group
Boston,
Massachusetts
| – | -$2.23M | -56,450 | Closed |
|
|
EI
80
EAM Investors
Solana Beach,
California
| – | -$1.5M | -37,871 | Closed |
|
|
RFC
81
Russell Frank Company
Seattle,
Washington
| – | -$840K | -18,345 | Closed |
|
|
FSA
82
Franklin Street Advisors
Chapel Hill,
North Carolina
| – | -$574K | -14,500 | Closed |
|
|
SAM
83
Sectoral Asset Management
Montreal,
Quebec, Canada
| – | -$389K | -9,827 | Closed |
|
84
Bank of America
Charlotte,
North Carolina
| – | +$632 | +14 | New |
|
XLRN Hedge Fund Activity: Q1 2014 in Review
79 of the 3,462 institutional investors tracked by Wall St. Rank reported a position in Acceleron Pharma (XLRN) for Q1 2014, worth a combined $593M — up 13% from $527M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new XLRN positions and 5 closed out — a net gain of 17 holders — while 29 added to existing stakes and 25 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $61.3M. The largest seller was JP Morgan Chase, cutting an estimated $11.7M.
- 79 institutional investors held Acceleron Pharma (XLRN) as of Q1 2014, up from 62 in Q4 2013.
- Funds reported $593M of Acceleron Pharma stock for Q1 2014, up 13% quarter-over-quarter.
- 22 funds opened new Acceleron Pharma positions in Q1 2014 and 5 closed out, a net change of +17 holders.
- The largest Acceleron Pharma buyer in Q1 2014 was T. Rowe Price Associates, an estimated $61.3M added.
- The largest Acceleron Pharma seller in Q1 2014 was JP Morgan Chase, an estimated $11.7M sold.
Based on aggregated 13F filings for Q1 2014.